RecruitingNCT05059951
Chemotherapy With or Without Immune Checkpoint Inhibitors for Lung Cancer
Sponsor
Hunan Province Tumor Hospital
Enrollment
15,000 participants
Start Date
Oct 3, 2021
Study Type
OBSERVATIONAL
Summary
Although several clinical trials provide evidence for efficacy benefit for Checkpoint Inhibitors plus chemotherapy for lung cancer. However, there was rare evidence for clinical evidence in Hunan province.
Eligibility
Min Age: 18 Years
Plain Language Summary
Simplified for easier understanding
This study collects and analyzes data from lung cancer patients who receive chemotherapy with or without immunotherapy (immune checkpoint inhibitors). The goal is to better understand which patients respond best and why, using real-world treatment data.
**You may be eligible if...**
- You are 18 or older with a confirmed lung cancer diagnosis
- You are receiving or have received chemotherapy with or without immunotherapy
- You have measurable tumors on imaging and are in reasonably good health
**You may NOT be eligible if...**
- You do not meet the above criteria
- You are in very poor physical health (ECOG 2 or higher)
Talk to your doctor to see if this trial is right for you.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGImmune checkpoint inhibitor
Chemotherapy follow the guild line.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05059951